title: Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.
abstract: RG7652 is a fully humanized monoclonal antibody targeting human PCSK9, a regulator of serum low density lipoprotein cholesterol (LDLc) levels. RG7652 prevents degradation of the hepatic LDLc receptors by blocking PCSK9 binding and thereby resulting in efficient LDLc uptake by hepatocytes. The pharmacokinetics of RG7652 have been evaluated in healthy subjects after single and multiple subcutaneous doses. Pharmacokinetic (PK) and pharmacodynamic (PD) models were developed to explain the antibody PK and LDLc time course data. The PK and PD models based on data from healthy subjects were used to simulate the effects of RG7652 on LDLc levels for a range of potential dose regimens in patients with coronary heart disease. A one-compartment PK model combined with an indirect PD response model was able to adequately describe the PK and LDLc data. Simulations of 400 mg every 4 weeks or 800 mg every 8 weeks regimens show significant LDLc reduction and suggest that dosing RG7652 once every month or once every 2 months is predicted to be optimal for the treatment of hypercholesterolemia. The PK and PD model successfully described the PK and LDLc data from healthy subjects in a Phase 1 study, and the model-based simulations provided useful insights and quantitative understanding for the selection of Phase 2 study doses in patients with coronary heart disease. The approach used in the case study demonstrates the utility of modeling and simulation in designing dose-ranging studies.
authors.affiliation: Clinical Pharmacology, Genentech Inc., 1 DNA Way, MS # 463a, S., San Francisco, California, 94080, USA.
authors.forename: Nageshwar R
authors.initials: NR
authors.lastname: Budha
authors.forename: Maya
authors.initials: M
authors.lastname: Leabman
authors.forename: Jin Y
authors.initials: JY
authors.lastname: Jin
authors.forename: D Russell
authors.initials: DR
authors.lastname: Wada
authors.forename: Amos
authors.initials: A
authors.lastname: Baruch
authors.forename: Kun
authors.initials: K
authors.lastname: Peng
authors.forename: Whittemore G
authors.initials: WG
authors.lastname: Tingley
authors.forename: John D
authors.initials: JD
authors.lastname: Davis
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL / Q000097:blood; D003198:Computer Simulation; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*; D012697:Serine Endopeptidases; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; C000600650:RG7652; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases
references.citation: Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1454-9
references.pmid: 15178557
references.citation: J Biol Chem. 2010 Dec 24;285(52):40965-78
references.pmid: 20937814
references.citation: Lancet. 2005 Oct 8;366(9493):1267-78
references.pmid: 16214597
references.citation: AAPS J. 2008 Dec;10(4):552-9
references.pmid: 19003542
references.citation: J Lipid Res. 2008 Feb;49(2):394-8
references.pmid: 18033751
references.citation: Atherosclerosis. 2007 Aug;193(2):445-8
references.pmid: 16989838
references.citation: Eur Heart J. 2011 Jul;32(14):1769-818
references.pmid: 21712404
references.citation: J Clin Lipidol. 2012 Jul-Aug;6(4):303-9
references.pmid: 22836065
references.citation: Eur Heart J. 2007 Mar;28(6):664-72
references.pmid: 17242008
references.citation: Eur Heart J. 2012 Jul;33(13):1635-701
references.pmid: 22555213
references.citation: Circulation. 2002 Dec 17;106(25):3143-421
references.pmid: 12485966
references.citation: Am J Hum Genet. 2006 Sep;79(3):514-23
references.pmid: 16909389
references.citation: AAPS J. 2005 Oct 07;7(3):E544-59
references.pmid: 16353932
references.citation: Clin Chem. 2012 Mar;58(3):619-27
references.pmid: 22249652
references.citation: Circulation. 2004 Jul 13;110(2):227-39
references.pmid: 15249516
references.citation: Nat Genet. 2005 Feb;37(2):161-5
references.pmid: 15654334
references.citation: N Engl J Med. 2006 Mar 23;354(12):1264-72
references.pmid: 16554528
references.citation: Annu Rev Pharmacol Toxicol. 2000;40:67-95
references.pmid: 10836128
references.citation: Am J Cardiol. 1998 Nov 19;82(10A):28S-30S
references.pmid: 9860353
references.citation: J Am Heart Assoc. 2012 Dec;1(6):e001800
references.pmid: 23316314
references.citation: Int J Clin Pract. 2003 Jun;57(5):363-8
references.pmid: 12846338
references.citation: Clin Pharmacol Ther. 1997 Mar;61(3):275-91
references.pmid: 9084453
references.citation: J Lipid Res. 2008 Jun;49(6):1152-6
references.pmid: 18375913
references.citation: N Engl J Med. 2014 Jan 16;370(3):275-8
references.pmid: 24283199
references.citation: J Pharmacokinet Biopharm. 1996 Dec;24(6):611-35
references.pmid: 9300353
references.citation: J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53
references.pmid: 22463922
references.citation: Expert Rev Cardiovasc Ther. 2006 Nov;4(6):917-26
references.pmid: 17173505
references.citation: J Lipid Res. 2009 Apr;50 Suppl:S172-7
references.pmid: 19020338
references.citation: Lancet. 2012 Dec 8;380(9858):2007-17
references.pmid: 23141813
references.citation: Clin Cardiol. 2002 Mar;25(3):89-90
references.pmid: 11890375
references.citation: Expert Opin Pharmacother. 2011 Jan;12(1):99-117
references.pmid: 21108580